Call for health systems to join initiatives to improve care
for specific patient populations
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare
improvement company, have expanded their efforts to co-develop and
test solutions to help improve patient care and wellness while
lowering healthcare spending.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170622005125/en/
In 2016, Merck and Premier agreed to collaborate to develop and
assess solutions that promote wellness and better care for specific
groups of at-risk patients across the continuum. The organizations
have now launched two projects under this collaboration model. One
is a preventive care model that seeks to improve adolescent and
adult vaccination rates. The other is a chronic disease model that
includes a new focus on type 2 diabetes patients at risk of
hypoglycemia, as well as osteoporosis identification and treatment
(as announced in 2016).
“Our expanded collaboration allows us to more effectively
support health systems and clinicians that are evolving from volume
to value-based models, but lack adequate prevention and wellness
solutions,” said Mimi Huizinga, MD, chief health information
officer at Premier. “We’ve been working with Merck to design
data-driven interventions for some of the top population health
challenges facing our country, and we’re eager to start testing
them in the real world.”
The vaccination and chronic care models combine the improvement
expertise and technical capabilities of Premier with Merck’s
education and therapeutic area expertise. The companies are now
developing plans with interested health systems to test these
models on the frontline, in real-world settings.
Vaccination Rates
Immunization is considered one of the most important public
health achievements of the last century, but vaccination rates
among adults and adolescents remain low in the U.S. The vaccination
solution will calculate vaccination rates, and provide performance
reports and education to help providers increase vaccination levels
among adults and adolescents.
“Vaccination administration happens across the continuum of
care, which can create challenges for healthcare providers to track
patient progress. The ability to use Premier’s analytics platform
allows for aggregation of data from multiple care sites so that
overall performance can be monitored,” said Lisa French, associate
vice president, strategy and commercial model innovation,
Merck.
Dr. Huizinga added, “Combining this care management technology
with educational resources from Merck will help ensure that adult
and adolescent vaccines reach more individuals who need them.”
Chronic Care
The chronic care solution currently targets two disease areas,
osteoporosis and type 2 diabetes. It is estimated that nearly 30
million people are living with diabetes in the U.S., and many
require medical intervention to treat hypoglycemia every year.
Additionally, there are approximately 10 million Americans with
osteoporosis, which is estimated to be responsible for two million
broken bones and $19 billion in U.S. healthcare costs each
year.
Merck and Premier will develop core sets of measures for
patients at-risk for these conditions across multiple sites of
care. In both cases, they will use a cloud-based application to
support guideline-based care. For example, the hypoglycemia
application will collect information from patients regarding their
hypoglycemia symptoms to improve the care team’s understanding of
the patient’s current state with the goal of improving the overall
management of their type 2 diabetes.
The vaccination and chronic care model solutions will be tested
within volunteer Premier member health systems. Merck and Premier
welcome interested healthcare organizations to inquire about
participation.
“Chronic diseases account for the vast majority of healthcare
costs in the U.S. and vaccination rates for adults and adolescents
are low, leaving millions of Americans unprotected from preventable
diseases,” said French. “Developing prevention programs and other
interventions that health systems can implement as part of their
population health management strategies can go a long way toward
helping improve patient care and wellness.”
The financial terms of the collaboration were not disclosed.
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us
on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About Premier Inc.
Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement
company, uniting an alliance of approximately 3,750 U.S. hospitals
and more than 130,000 other provider organizations. With integrated
data and analytics, collaboratives, supply chain solutions, and
advisory and other services, Premier enables better care and
outcomes at a lower cost. Premier, a Malcolm Baldrige National
Quality Award recipient, plays a critical role in the rapidly
evolving healthcare industry, collaborating with members to
co-develop long-term innovations that reinvent and improve the way
care is delivered to patients nationwide. Headquartered in
Charlotte, N.C., Premier is passionate about transforming American
healthcare. Please visit Premier’s news and investor sites on
www.premierinc.com.
Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the companies’ patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2016
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
Forward-looking statements of Premier Inc.
Matters discussed in this release that are not statements of
historical or current facts, as discussed herein, are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause the actual results, performance or
achievements of Premier to be materially different from historical
results or from any future results or projections expressed or
implied by such forward-looking statements. Accordingly, readers
should not place undue reliance on any forward looking statements.
In addition to statements that explicitly describe such risks and
uncertainties, readers are urged to consider statements in the
conditional or future tenses or that include terms such as
“believes,” “belief,” “expects,” “estimates,” “intends,”
“anticipates” or “plans” to be uncertain and forward-looking.
Forward-looking statements may include comments as to Premier’s
beliefs and expectations as to future events and trends affecting
its business and are necessarily subject to uncertainties, many of
which are outside Premier’s control. More information on potential
factors that could affect Premier’s financial results is included
from time to time in the “Forward Looking Statements,” “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” sections of Premier’s periodic
and current filings with the SEC and available on Premier’s website
at investors.premierinc.com. Forward looking statements speak only
as of the date they are made. Premier undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise that
occur after that date.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170622005125/en/
Premier Inc.Public Relations:Morgan Guthrie,
704-816-4152Morgan_Guthrie@PremierInc.comorMerckGlobal
Communications:Patrick Witmer,
267-305-4910Patrick_Witmer@Merck.comorMedia Relations:Pamela
Eisele, 267-305-3558Pamela_Eisele@Merck.comorInvestor
Relations:Teri Loxam, 908-740-1986Teri.Loxam@Merck.comorInvestor
Relations:Amy Klug, 908-740-1898Amy_Klug@Merck.com
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024